



CIN : L65910MH1992PLC067632

Date: 13th February, 2023

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 511523

Sub.: Unaudited Financial Results for the quarter and nine months ended December 31, 2022

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing Unaudited Financial Results for the quarter and nine months ended December 31, 2022.
2. Limited Review Report on Unaudited Financial Results for the quarter and nine months ended December 31, 2022.

Thanking You.

Yours faithfully,
For Veerhealth Care Limited

Bhavin S. Shah
Managing Director
DIN: 03129574



Encl: As above

Statement of Unaudited Financial Results for the Quarter and Nine months ended December 31, 2022

(Rs. in lakhs)

Sr. No.	Particulars	Standalone					
		Quarter ended 31-12-2022	Quarter ended 30-09-2022	Quarter ended 31-12-2021	Nine Months ended 31-12-2022	Nine Months ended 31-12-2021	Year ended 31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	275.45	392.84	264.96	953.92	761.15	962.61
II	Other Income	35.19	41.53	44.01	96.44	104.07	166.74
III	Total Revenue (I + II)	310.64	434.37	308.97	1050.36	865.22	1129.35
IV	Expenses:						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	246.01	216.21	157.76	710.80	522.89	738.33
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-59.05	66.55	40.42	-45.99	30.78	-46.10
	(d) Employee benefits expense	27.18	20.31	23.54	69.28	57.84	87.75
	(e) Finance Costs	0.06	0.00	0.08	0.09	4.68	8.51
	(f) Depreciation and amortisation expense	15.82	15.43	13.30	45.99	39.04	52.42
	(g) Other expenses	44.87	96.84	55.12	204.64	181.82	264.68
	Total Expenses	274.89	415.34	290.22	984.81	837.05	1105.59
V	Profit/(Loss) before exceptional items (III - IV)	35.75	19.03	18.75	65.55	28.17	23.76
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	35.75	19.03	18.75	65.55	28.17	23.76
VIII	Tax expense:						
	1) Current Tax	2.65	5.00	1.60	9.15	3.00	3.75
	2) Prior Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
	3) Deferred Tax	0.15	0.29	0.00	0.44	0.00	29.65
IX	Profit/(Loss) for the period (VII - VIII)	32.95	13.74	17.15	55.96	25.17	-9.64
X	Other Comprehensive Income						
	(a) Items that will not be reclassified to Profit or Loss	-0.86	-0.86	-2.43	-2.59	-7.28	8.07
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00	0.00
	Other Comprehensive Income	-0.86	-0.86	-2.43	-2.59	-7.28	8.07
XI	Total Comprehensive Income for the period (IX + X)	32.09	12.88	14.72	53.37	17.89	-1.57
XII	Paid-up equity share capital of Rs. 10 each	693.42	693.42	693.42	693.42	693.42	693.42
XIII	Other Equity						701.64
XIV	Net Worth						1395.06
XV	Earnings Per Share (of Rs. 10 each):						
	(a) Basic (in Rs.)	0.46	0.19	0.25	0.77	0.36	-0.14
	(b) Diluted (in Rs.)	0.46	0.19	0.25	0.77	0.36	-0.14



Trained

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.
Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632
Email: info@veerhealthcare.net Website: www.veerhealthcare.net

NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th February, 2023. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 During the quarter ended December 31, 2022 the Company is operating in a single segment i.e. "Ayurved Pharma Products". Accordingly, segment wise reporting is not applicable.
- 4 Figures of the previous periods have been rearranged / regrouped, wherever necessary.
- 5 The financial results of the Company are available at www.bseindia.com and at www.veerhealthcare.net.

Place: Mumbai
Date: 13th February, 2023



By order of the Board
For Veerhealth Care Limited

A handwritten signature in black ink, appearing to read "Bhavin S. Shah".

Bhavin S. Shah
Managing Director
DIN: 03129574

Limited Review Report

To the Board of Directors of Veerhealth Care Limited

I have reviewed the accompanying statement of Unaudited Standalone Ind-AS Financial Results of M/s. Veerhealth Care Limited ("the Company") for the quarter and year to date ended 31st December, 2022, together with the notes thereon attached herewith ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

I conducted my review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.


A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. I have not performed an audit and accordingly I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of Audited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jayesh R Shah & Co.
Chartered Accountants
Firm Regn. No.104182W



Jayesh Shah
Proprietor
Membership No.033864



Place: Mumbai
Date: 13th February, 2023
UDIN: 23033864BGYCRE1399